Which Therapy for Helicobacter pylori Infection? (Q36060733)

11 August 2017

0 references

Which Therapy for Helicobacter pylori Infection? (English)

1 reference

Helicobacter pylori infectious disease

11 August 2017

0 references

1 reference

1

David Y Graham

1 reference

11 August 2017

2

Akiko Shiotani

1 reference

PMCID

3383941

11 August 2017

language of work or name

English

0 references

publication date

18 May 2012

1 reference

11 August 2017

1 reference

11 August 2017

143

1 reference

11 August 2017

10-12

1 reference

11 August 2017

1

1 reference

Increasing the duration of dual amoxicillin plus omeprazole Helicobacter pylori eradication to 6 weeks: a pilot study

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383941

Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383941

Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383941

Helicobacter pylori treatment in the era of increasing antibiotic resistance

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383941

Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383941

Efficient identification and evaluation of effective Helicobacter pylori therapies

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383941

Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383941

Understanding and appreciating sequential therapy for Helicobacter pylori eradication

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383941

Helicobacter pylori therapy demystified

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383941

Helicobacter pylori eradication therapy research: Ethical issues and description of results

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383941

Editorial: Sequential therapy for eradication of Helicobacter pylori: a new guiding light or a false dawn?

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383941

Comparison of the Etest and the NCCLS-approved agar dilution method to detect metronidazole and clarithromycin resistant Helicobacter pylori

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383941

The MACH2 study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies

23 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22613622

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22613622

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22613622

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1053/J.GASTRO.2012.05.012

1 reference

11 August 2017

1 reference

11 August 2017

1 reference

PMCID

3383941